TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06249048: Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Sponsor: Strand Therapeutics Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 108 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$8,835,750

Rescue Site Savings

+$5,811,960

Unlock Full NCT06249048 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06249048 Rescue Dossier →